The Biggest Surprises of 2006
This article was originally published in RPM Report
Executive Summary
When Wall Street analysts were asked to weigh in on the top events of 2006, they were right about many of their predictions. But there were a few that caught everyone off guard: the FDA approval prospects of Sandoz' follow-on human growth hormone Omnitrope and Sanofi-Aventis' weight loss drug rimonabant.
You may also be interested in...
The Approval Drought Continues
No matter how you look at the numbers, it was another bad year for new product launches in the US. FDA approved more new drugs than last year, but just barely. And the number of products going off-patent actually exceeded the number of new launches. The sparse crop of new drugs this decade means lean years ahead for the pharma industry.
Wall Street Looks Ahead: Market-Moving Events that Will Shape 2007
Wall Street analysts are confident that Congress will pass drug safety legislation this year, but in a poll conducted by The RPM Report, they didn't agree on much else. The panel was split most other questions-from whether Congress would remove the "non-interference" clause under Medicare Part D to whether FDA would approve another cox-2 inhibitor.
The Acomplia Paradox: Primary Care Drug, Targeted Population
As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.